Blueprint Medicines is a precision therapy company that develops medicines for genomically defined cancers and blood disorders. They are developing various drugs for the treatment of different types of cancers, including AYVAKIT, BLU-263, Fisogatinib, GAVRETO, BLU-701, BLU-945, BLU-451, BLU-782, BLU-222, and BLU-852. The company has collaboration and license agreements with various pharmaceutical companies. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.